Royalty revenue increased by 1% to $64.8 million for the three months to June 30, 2008 (2007: $64.0 million). The following table provides an analysis of Shire's royalty income:
to Shire Growth(1)
Product $M %
3TC 35.6 -9%
ZEFFIX 10.8 4%
Other 18.4 26%
Total 64.8 1%
(1) Compared with Q2 2007.
3TC - HIV infection and AIDS
Shire receives royalties from GSK on worldwide 3TC sales. Royalties from sales of 3TC for the three months to June 30, 2008 were $35.6 million, (2007: $39.0 million). Excluding favorable foreign exchange movements of 7%, there has been a decline of 16% compared to the same period in 2007. While the nucleoside analogue market for HIV has continued to grow, competitive pressures from new products and entrants to the market have increased, leading to a decline in 3TC sales.
ZEFFIX - Chronic hepatitis B infection
Shire receives royalties from GSK on worldwide ZEFFIX sales. Royalties from sales of ZEFFIX for the three months to June 30, 2008 were $10.8 million, an increase of 4% (2007: $10.4 million). The impact of foreign exchange movements has contributed 13% to the reported growth; excluding favorable foreign exchange movements there has been a decrease of 9% compared to the same period in 2007.
Other royalties are primarily in respect of REMINYL and REMINYL XL
(known as RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide
(excluding the UK and the Republic of Ireland) b
|SOURCE Shire Ltd|
Copyright©2008 PR Newswire.
All rights reserved